BioCentury
ARTICLE | Company News

Lilly returns diabetes candidate to Adocia

January 27, 2017 11:13 PM UTC

Adocia S.A. (Euronext:ADOC) sank EUR 12.67 (31%) to EUR 27.60 after it said Eli Lilly and Co. (NYSE:LLY) terminated a 2014 deal and returned rights to Adocia's BioChaperone Lispro to treat Type I and Type II diabetes. Lilly had paid $50 million upfront for exclusive, worldwide rights to the ultra-fast acting formulation of insulin lispro using BioChaperone polymer technology (see BioCentury Extra, Dec. 19, 2014).

Adocia said it will continue preparations for Phase III testing of BioChaperone Lispro while seeking a new partner...

BCIQ Company Profiles

Adocia S.A.

Eli Lilly and Co.

BCIQ Target Profiles

Insulin receptor (INSR)